natgillin/translations-raw huggingface dataset:
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from
Farmakokinetične lastnosti pemetrekseda po dajanju ene učinkovine so vrednotili pri 426 bolnikih z različnimi malignimi trdnimi tumorji v razponu odmerkov od 0,2 do 838 mg/m2, infundiranih v
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to
Farmakokinetične lastnosti pemetrekseda po dajanju ene učinkovine so vrednotili pri 426 bolnikih z različnimi malignimi trdnimi tumorji v razponu odmerkov od 0,2 do 838 mg/m2, infundiranih v
The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to
Farmakokinetične lastnosti pemetrekseda po dajanju ene učinkovine so vrednotili pri 426 bolnikih z različnimi malignimi trdnimi tumorji v razponu odmerkov od 0,2 do 838 mg/m², infundiranih v
The pharmacokinetic properties of Ryzodeg in type 1 diabetes mellitus were investigated in children (6–11 years) and adolescents (12–18 years) and compared to adults after single dose administration.
Farmakokinetične lastnosti zdravila Ryzodeg pri zdravljenju sladkorne bolezni tipa 1 so raziskali pri otrocih (od 6. do 11. leta) in mladostnikih (od 12. do 18. leta) in jih primerjali s tistimi pri odraslih po aplikaciji enega odmerka.
The pharmacokinetic properties of secukinumab observed in ankylosing spondylitis patients were similar to those displayed in plaque psoriasis patients.
Farmakokinetične lastnosti sekukinumaba, ki so jih opažali pri bolnikih z ankilozirajočim spondilitisom, so bile približno enake kot pri bolnikih s psoriazo s plaki.
The pharmacokinetic properties of secukinumab observed in psoriatic arthritis patients were similar to those displayed in plaque psoriasis patients.
Farmakokinetične lastnosti sekukinumaba, ki so jih opažali pri bolnikih s psoriatičnim artritisom, so bile približno enake kot pri bolnikih s psoriazo s plaki.
The pharmacokinetic properties of simeprevir have been evaluated in healthy adult subjects and in adult HCV infected patients.
Farmakokinetične lastnosti simeprevirja so ocenjevali pri zdravih odraslih in pri odraslih bolnikih, okuženih s HCV.
The pharmacokinetic properties of telaprevir have been evaluated in healthy adult volunteers and in subjects with chronic HCV infection.
Farmakokinetične lastnosti telaprevirja so bile ovrednotene pri zdravih odraslih prostovoljcih in pri bolnikih s kronično okužbo s HCV.
The pharmacokinetic properties of the combination of Viekirax with dasabuvir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 19 shows mean Cmax and AUC of Viekirax 25 mg/150 mg/100 mg once daily with dasabuvir 250 mg twice daily following multiple doses with food in healthy volunteers.
Farmakokinetične lastnosti kombinacije zdravila Viekirax in dasabuvirja so ocenili pri zdravih odraslih in pri bolnikih s kroničnim hepatitisom C. Preglednica 18 prikazuje povprečni Cmax in AUC za zdravilo Viekirax 25 mg/150 mg/100 mg enkrat na dan z dasabuvirjem 250 mg dvakrat na dan, po večkratnih odmerkih s hrano, pri zdravih prostovoljcih.
The pharmacokinetic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Farmakokinetične lastnosti z itrijem (90Y) označenega zdravila, pripravljenega z radioaktivnim označevanjem z radiofarmacevtskim predhodnikom Yttriga pred dajanjem, bodo odvisne od vrste zdravila, ki bo radioaktivno označevano.
The pharmacokinetic properties, use in special populations and drug-drug interactions for each of the individual components (lamivudine and raltegravir) are applicable to DUTREBIS.
Farmakokinetične lastnosti, uporaba v posebnih populacijah in medsebojna delovanja zdravil za vsako od obeh posameznih učinkovin (lamivudin in raltegravir) veljajo tudi za zdravilo DUTREBIS.
The pharmacokinetic results for the co primary endpoint, Ctrough at pre dose Cycle 8 (Ctrough), showed non-inferiority of the Herceptin subcutaneous compared to the Herceptin intravenous dose adjusted by body weight.
Farmakokinetični rezultati za eno od primarnih končnih ciljev, najnižjo koncentracijo pred 8. ciklom (ctrough), so pokazali neinferiornost subkutane oblike zdravila Herceptin v primerjavi z intravensko obliko zdravila Herceptin, prilagojeno glede na telesno maso.
The pharmacokinetic results for the co primary endpoint, Ctrough pre dose Cycle 8, showed non-inferiority of the Herceptin subcutaneous compared to the Herceptin intravenous dose adjusted by body weight.
Farmakokinetični rezultati za eno od primarnih končnih ciljev, najnižjo koncentracijo pred 8. ciklom, so pokazali neinferiornost subkutane oblike zdravila Herceptin v primerjavi z intravensko obliko zdravila Herceptin, prilagojeno glede na telesno maso.
The pharmacokinetic results of this study indicated a reduction of vinflunine clearance when CrCl is decreased.
Farmakokinetični rezultati te študije kažejo, da se pri zmanjšanem OK zmanjša tudi izločanje vinflunina..
The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and adult patients when normalized by body weight.
Farmakokinetični rezultati kažejo, da sta bila po normiranju glede na telesno maso očistek in volumen porazdelitve bevacizumaba med pediatričnimi in odraslimi bolniki primerljiva.
The pharmacokinetic variability observed in the elderly is within the range for the non- elderly.
Farmakokinetična variabilnost, opažena pri starejših, je v okvirih razpona za nestarejše.
The pharmacokinetic variables characterized by population pharmacokinetic analysis represent the overall hypophosphatasia patient population with age range from 1 day to 66 years, subcutaneous doses of up to 28 mg/kg/week and a range of disease onset cohorts.
Farmakokinetične spremenljivke, ki jih karakterizira populacijska farmakokinetična analiza, predstavljajo celokupno populacijo bolnikov s hipofosfatazijo z območjem starosti od 1 dneva do 66 let, subkutanimi odmerki do 28 mg/kg/teden in kohortami območja nastopa bolezni.
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day).
Farmakokinetično/farmakodinamsko razmerje (PK/PD) med plazemsko koncentracijo rivaroksabana in posameznimi farmakodinamičnimi končnimi točkami (zavrtje faktorja Xa, PČ, aPTČ, HepTest) so ocenjevali po uporabi več odmerkov (5 - 30 mg dvakrat na dan).
The pharmacokinetic/pharmacodynamic relationship in humans for IOP- lowering has not been established.
Farmakokinetičnih in farmakodinamičnih razmerij v zvezi z znižanjem očesnega tlaka pri človeku niso ugotavljali.
The pharmacokinetics (PK) of daratumumab following intravenous administration were evaluated in patients with relapsed and refractory multiple myeloma at dose levels from 0.1 mg/kg to 24 mg/kg.
Farmakokinetiko daratumumaba po intravenskem odmerjanju so pri bolnikih s ponovljenim in neodzivnim diseminiranim plazmocitomom ocenjevali pri odmernih ravneh od 0,1 mg/kg do 24 mg/kg.
The pharmacokinetics (PK) of nintedanib can be considered linear with respect to time (i.e. single- dose data can be extrapolated to multiple-dose data).
Farmakokinetiko nintedaniba je mogoče smatrati kot linearno glede na čas (to pomeni, da je podatke o enkratnem odmerku mogoče ekstrapolirati na podatke za večkratne odmerke).
The pharmacokinetics and dosing
Farmakokinetike in priporočil za
The pharmacokinetics and pharmacodynamics of dabigatran etexilate administered twice daily for three consecutive days (total 6 doses) at the end of standard anticoagulant therapy were assessed in an open-label safety and tolerability study in 9 stable adolescents (12 to < 18 years).
Farmakokinetiko in farmakodinamiko dabigatran eteksilata so pri dvakrat dnevnem dajanju tri zaporedne dni (skupno 6 odmerkov) ob koncu standardnega antikoagulacijskega zdravljenja ocenili v odprti raziskavi o varnosti in prenašanju pri 9 stabilnih mladostnikih (12 do < 18 let).
The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co- administration of mycophenolate mofetil (see also section 5.2).
Sočasno jemanje mofetilmikofenolata ni vplivalo na farmakokinetiko in farmakodinamiko peroralnih kontraceptivov (glejte poglavje 5.2).
The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co-administration of CellCept (see also section 5.2).
Sočasno jemanje zdravila CellCept ni vplivalo na farmakokinetiko in farmakodinamiko peroralnih kontraceptivov (glejte tudi poglavje 5.2).
The pharmacokinetics and safety of a single loading dose of iv lacosamide were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of lacosamide using a single iv loading dose (including 200 mg) followed by twice daily oral dosing (equivalent to the iv dose) as adjunctive therapy in adult subjects 16 to 60 years of age with partial-onset seizures.
Farmakokinetika in varnost enkratnega začetnega (polnilnega) odmerka lakozamida za intravensko uporabo sta bili določeni z multicentrično, odprto študijo, s katero so ocenili varnost in prenašanje hitrega vnosa lakozamida z uporabo enkratnega intravenskega začetnega (polnilnega) odmerka (vključuje 200 mg), ki mu sledi peroralno odmerjanje dvakrat na dan (ekvivalentno intravenskemu odmerku) kot dopolnilno zdravljenje pri odraslih osebah, starih od 16 do 60 let, s parcialnimi napadi.
The pharmacokinetics and systemic exposure to amifampridine is notably influenced by the overall metabolic acetylation activity of the polymorphic N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation (see section 5.2), as shown in the healthy volunteer study.
Na farmakokinetiko in sistemsko izpostavljenost amifampridinu bistveno vplivata splošna presnovna acetilacijska aktivnost polimorfnih encimov N-acetil-transferaze (NAT) (fenotip acetilatorja) in genotip NAT2, ki sta zaradi genetike različna (glejte poglavje 5.2), kot prikazuje študija z zdravimi prostovoljci.
The pharmacokinetics in paediatric subjects after multiple doses has not been studied.
Farmakokinetika pri pediatričnih preiskovancih po več odmerkih ni raziskana.
The pharmacokinetics in patients below the age of 18 has not been studied.
Farmakokinetike pri bolnikih, starih manj kot 18 let, niso preučili.
The pharmacokinetics in patients with renal or hepatic impairment has not been characterised.
Farmakokinetika pri bolnikih z ledvično ali jetrno okvaro ni bila določena.
The pharmacokinetics in patients with renal or hepatic impairment have not been characterised.
Farmakokinetika pri bolnikih z ledvično ali jetrno okvaro ni bila določena.
The pharmacokinetics is not altered with repeat dosing.
Pri ponavljajočih se odmerkih se farmakokinetika ne spremeni.
The pharmacokinetics of
Farmakokinetika zdravila Kaletra
The pharmacokinetics of a 20 mg single dose of bazedoxifene were evaluated in a study in 26 healthy postmenopausal women.
Farmakokinetiko enkratnega 20 mg odmerka bazedoksifena so ocenili v študiji pri 26 zdravih ženskah v postmenopavzi.
The pharmacokinetics of a single 4 mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (Child-Pugh class A; n=9) or moderate (Child-Pugh class B; n=8) hepatic impairment and in age- ,sex-, and weight-matched healthy adults with normal hepatic function (n=19).
Farmakokinetiko enkratnega 4 mg odmerka mifamurtida po 1 urnem intravenskem infundiranju so vrednotili pri odraslih prostovoljcih z blago (Child-Pugh razred A, n=9) ali zmerno (Child-Pugh razred B, n=8) okvaro jeter in pri po starosti, spolu in telesni masi primerljivih zdravih odraslih osebah z normalnim delovanjem jeter (n=19).
The pharmacokinetics of a single 4mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (n=9) or moderate (n=8) renal impairment and in age- , sex-, and weight-matched healthy adults with normal renal function (n=16).
Farmakokinetiko enkratnega 4 mg odmerka mifamurtida po 1 urnem intravenskem infundiranju so vrednotili pri odraslih prostovoljcih z blago (n=9) ali zmerno (n=8) okvaro ledvic in pri po starosti, spolu in telesni masi primerljivih zdravih odraslih osebah z normalnim delovanjem ledvic (n=16).
The pharmacokinetics of A771726 following oral administration of leflunomide have been investigated in 73 paediatric patients with polyarticular course Juvenile Rheumatoid Arthrit is (JRA) who ranged in age from 3 to 17 years.
Farmakokinetiko A771726 po peroralni uporabi leflunomida so raziskali pri 73 pediatričnih bolnikih, starih od 3 do 17 let, ki so imeli juvenilni revmatoidni artritis (JRA) s poliartikularnim potekom.
The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose.
Farmakokinetične lastnosti abakavirja so preučevali pri bolnikih z blago jetrno okvaro (Child-Pugh ocena 5–6 ), ki so prejeli abakavir v enkratnem 600 mg odmerku.
The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver disease.
Pri bolnikih z blago do hudo boleznijo jeter ni prišlo do pomembnega vpliva na farmakokinetične lastnosti aliskirena.
The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment; therefore, caution should be exercised when administering Rasilamlo to patients with hepatic impairment.
Pri bolnikih s hudo okvaro jeter niso proučevali farmakokinetike amlodipina, zato je pri uporabi zdravila Rasilamlo pri bolnikih z okvaro jeter potrebna previdnost.
The pharmacokinetics of anidulafungin are characterised by a rapid distribution half-life (0.5-1 hour) and a volume of distribution, 30-50 l, which is similar to total body fluid volume.
Za farmakokinetiko anidulafungina sta značilna kratek razpolovni čas porazdelitve (0,5–1 uro) in volumen porazdelitve od 30 do 50 l, kar je podobno celotnemu volumnu tekočine v telesu.
The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects based on population pharmacokinetic analyses.
Pri bolnikih z glivičnimi okužbami je farmakokinetika anidulafungina podobna farmakokinetiki pri zdravih preiskovancih, ugotovljeni na podlagi analiz populacijske farmakokinetike.
The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.
Farmakokinetika avibaktama ni raziskana pri bolnikih s katero koli stopnjo okvare jeter.
The pharmacokinetics of azilsartan have not been studied in children under 18 years of age.
Farmakokinetika azilsartana ni bila preučevana pri otrocih, mlajših od 18 let.
The pharmacokinetics of bazedoxifene have not been studied in the paediatric population.
Pri pediatrični populaciji farmakokinetike bazedoksifena niso proučevali.
The pharmacokinetics of bortezomib are not influenced in patients with mild to moderate renal impairment (Creatinine Clearance [CrCL] > 20 ml/min/1.73 m2); therefore, dose adjustments are not necessary for these patients.
Pri bolnikih z blago do zmerno okvaro ledvic (očistek kreatinina [CrCL] > 20 ml/min/1,73 m2) farmakokinetika bortezomiba ni spremenjena, zato pri njih ni potrebno prilagajati odmerka.
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 paediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Farmakokinetiko bortezomiba so ovrednotili po intravenski aplikaciji bolusnega odmerka 1,3 mg/m2 dvakrat na teden 104 pediatričnim bolnikom (starim 2-16 let) z akutno limfoblastno levkemijo (ALLAcute Lymphoblastic Leukemia) ali akutno mieloično levkemijo (AML- Acute Myeloid Leukemia).
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 paediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Farmakokinetiko bortozomiba so ovrednotili po intravenski aplikaciji bolusnega odmerka 1,3 mg/m2 dvakrat na teden 104 pediatričnim bolnikom (starim 2-16 let) z akutno limfoblastno levkemijo (ALLAcute Lymphoblastic Leukemia) ali z akutno mieloično levkemijo (AML- Acute Myeloid Leukemia).
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Farmakokinetiko bortezomiba so ovrednotili po intravenski aplikaciji bolusnega odmerka 1,3 mg/m2 dvakrat na teden 104 pediatričnim bolnikom (starim 2–16 let) z akutno limfoblastno levkemijo (ALL – Acute Lymphoblastic Leukemia) ali z akutno mieloično levkemijo (AML – Acute Myeloid Leukemia).
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Farmakokinetiko bortozomiba so ovrednotili po intravenski aplikaciji bolusnega odmerka 1,3 mg/m2 dvakrat na teden 104 pediatričnim bolnikom (starim 2-16 let) z akutno limfoblastno levkemijo (ALL - Acute Lymphoblastic Leukemia) ali z akutno mieloično levkemijo (AML - Acute Myeloid Leukemia).
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Farmakokinetiko bortozomiba so ovrednotili po intravenski aplikaciji bolusnega odmerka 1,3 mg/m2 dvakrat na teden 104 pediatričnim bolnikom (starim 2-16 let) z akutno limfoblastno levkemijo (ALL- Acute Lymphoblastic Leukemia) ali z akutno mieloično levkemijo (AML- Acute Myeloid Leukemia).
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, , Asian) in a population pharmacokinetic modeling from epilepsy patients.
Rasa (belci, Azijci) ni pomembno vplivala na farmakokinetiko brivaracetama v modeliranju populacijske farmakokinetike pri bolnikih z epilepsijo.
The pharmacokinetics of Caelyx over the dose range of 10 mg/m2 to 60 mg/m2 was best described by a two compartment non-linear model with zero order input and Michaelis-Menten elimination.
Farmakokinetiko zdravila Caelyx v odmernem območju od 10 do 60 mg/m2 najbolje opiše dvoprostorni nelinearni model z vnosom ničelnega reda in Michaelis- Mentenovim izločanjem.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in patients with renal impairment.
Farmakokinetike CE/bazedoksifena pri bolnicah z okvaro ledvic niso raziskovali.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in patients with renal impairment.
Farmakokinetike kombinacije CE/bazedoksifena pri bolnicah z okvaro ledvic niso raziskovali.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in women over 75 years of age.
Farmakokinetike kombinacije CE/bazedoksifena pri ženskah, starejših od 75 let, niso ocenjevali.
The pharmacokinetics of CE/bazedoxifene have not been evaluated in women with hepatic impairment.
Farmakokinetike kombinacije CE/bazedoksifena pri bolnicah z okvaro jeter niso raziskovali.
The pharmacokinetics of ceftaroline was similar between males and females.
Farmakokinetika ceftarolina je pri moških in ženskah podobna.
The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.
Spol in rasa nimata pomembnega vpliva na farmakokinetiko kombinacije ceftazidim/avibaktam.
The pharmacokinetics of ceritinib have not been studied in patients with moderate to severe hepatic impairment.
Pri bolnikih z zmerno do hudo okvaro jeter farmakokinetike ceritiniba niso proučevali.
The pharmacokinetics of cinacalcet have been studied in 12 paediatric patients (6-17 years) with CKD receiving dialysis following a single, oral, 15 mg dose.
Farmakokinetiko cinakalceta po enem peroralnem odmerku 15 mg so raziskali pri 12 pediatričnih bolnikih (starih 6-17 let) s kronično boleznijo ledvic, zdravljenih z dializo.
The pharmacokinetics of dalbavancin were evaluated in 17 subjects with mild, moderate, or severe hepatic impairment and compared to 9 matched healthy subjects with normal hepatic function.
Farmakokinetika dalbavancina je bila ocenjena pri 17 osebah z blago, zmerno ali hudo okvaro jeter in pri 9 osebah v kontrolni skupini z normalnim delovanjem jeter.
The pharmacokinetics of daptomycin after a single 4 mg/kg dose of Cubicin were evaluated in three groups of paediatric patients with proven or suspected Gram-positive infection (2-6 years, 7-11 years and 12-17 years).
Farmakokinetične lastnosti daptomicina po enkratnem odmerku 4 mg/kg zdravila Cubicin so ocenjevali pri treh skupinah pediatričnih bolnikov z dokazano okužbo s po Gramu pozitivnimi bakterijami ali s sumom na tako okužbo (starih 2-6 let, 7-11 let in 12-17 let).
The pharmacokinetics of daptomycin appears to be linear in the dose range studied.
Kaže, da je farmakokinetika daptomicina v okviru proučevanih odmerkov linearna.
The pharmacokinetics of daptomycin following a single 4 mg/kg dose in adolescents aged 12-17 years are generally similar to those of healthy adult subjects with normal renal function with trends towards lower AUC and Cmax in adolescents.
Pri mladostnikih, starih 12-17 let, so farmakokinetične lastnosti daptomicina po enkratnem odmerku 4 mg/kg v glavnem enake kot pri zdravih odraslih z normalnim delovanjem ledvic, s tem da pri mladostnikih AUC in Cmax kažeta trend zniževanja.
The pharmacokinetics of darifenacin have not been established in the paediatric population.
V pediatrični populaciji farmakokinetike darifenacina niso ugotavljali.
The pharmacokinetics of decitabine following intravenous administration as a 1-hour infusion were described by a linear two-compartment model, characterised by rapid elimination of the drug from the central compartment and by relatively slow distribution from the peripheral compartment.
Farmakokinetiko decitabina po enourni aplikaciji intravenske infuzije so opisovali s pomočjo linearnega dvoprostornega modela, in sicer jo označuje hitro izločanje zdravila iz centralnega prostora in razmeroma počasna porazdelitev iz perifernega prostora.
The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).
Farmakokinetika deferasiroksa pri starejših bolnikih (starih 65 let ali več) ni bila proučena.
The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single-dose study and one multiple dose study.
Farmakokinetiko desloratadina pri bolnikih s kronično ledvično insuficienco (CRI – chronic renal insufficiency) so v eni študiji z enkratnim odmerkom in eni študiji z večkratnimi odmerki primerjali s farmakokinetiko pri zdravih preiskovancih.
The pharmacokinetics of dinutuximab were evaluated in a clinical study of Unituxin in combination with GM-CSF, IL-2, and isotretinoin.
Farmakokinetika dinutuksimaba je bila ocenjena v klinični študiji o zdravilu Unituxin v kombinaciji z GM- CSF, IL-2 in izotretinoinom.
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of
Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20-115 mg/m² v študijah
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of
Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20–115 mg/m2 v študijah
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of
Farmakokinetiko docetaksela so ocenili pri onkoloških bolnikih po uporabi 20–115 mg/m2 v študijah I. faze.